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Familial hypercholesterolemia (FH, OMIM no. 143890) is a 
common autosomal dominant condition with a prevalence of 
1 in 500. Patients with FH have raised serum cholesterol lev-
els and increased arterial deposition of low-density lipoprotein 
(LDL) cholesterol, leading to premature coronary heart disease. 
Despite the fact that early-onset coronary heart disease can be 
prevented by cholesterol-lowering drugs such as statins, less 
than a quarter of FH patients have currently been identified 
in the United Kingdom.1 Several diagnostic criteria have been 
developed to identify individuals with FH, including the Dutch 
Lipid Clinic2 criteria and the MedPed3 criteria. In the United 
Kingdom, the clinical diagnosis of FH is based on the Simon 
Broome criteria of cholesterol levels, presence of tendon xan-
thomata, family history, and genetic testing.4 The UK National 
Institute for Health and Clinical Excellence guidelines recom-
mend initial mutation screening of index cases fulfilling Simon 
Broome criteria followed by cascade screening in at least first- 
and second-degree relatives.5
Most cases of FH are caused by mutations in the LDLR gene 
that encodes the LDL receptor protein, which binds LDL par-
ticles at the hepatic cell membrane and internalizes them for 
processing and excretion. FH-causing mutations in LDLR are 
found throughout the gene and include missense, truncating, 
and splice site mutations; small insertion/deletion mutations; 
and large insertions/deletions that can encompass multiple 
exons. Some mutations have been found in many unre-
lated individuals with FH, whereas others are found rarely.6 
Mutations in two other genes, PCSK9 and APOB, can also 
cause the FH phenotype but in <20% of cases.7 Rare auto-
somal-recessive hypercholesterolemia is caused by mutations 
in the LDLRAP1 gene.8
Conventional DNA testing of FH disease–causing genes is 
mostly based on direct capillary sequencing, with multiplex 
ligation-dependent probe amplification (MLPA) used for the 
detection of large insertions or deletions.9 These molecular 
techniques are sensitive and specific, but because of the cost and 
time involved, they are impractical for screening large numbers 
of patients. To overcome some of these limitations, assays such 
as the Amplification Refractory Mutation System (Elucigene 
FH20; Tepnel Molecular Diagnostics, Abingdon, UK) or array-
based sequencing methods (LIPOchip; Progenika Biopharma, 
Derio, Spain) have been developed. These assays are tailored to 
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specific mutations and populations and therefore do not detect 
less common mutations or any novel mutations.10,11
During the past few years, high-throughput next-gen-
eration sequencing (NGS)–based methods have become 
available for DNA analysis. They have not only proven suc-
cessful in new disease gene identification, but following 
the availability of economic “benchtop” sequencers, they 
have become more easily applicable to targeted diagnostic 
sequencing. The combination of high-throughput and rela-
tively small DNA target selection allows for many genes and 
samples to be processed simultaneously, making it an attrac-
tive solution for the processing of large sample numbers in a 
diagnostic laboratory. Moreover, the flexible design of these 
assays enables molecular screening to be extended to other 
relevant genes and polymorphisms that are not covered by 
routine tests.
In this study, two target enrichment protocols, the hybrid-
ization-based SureSelect Target Enrichment System and the 
PCR-based Access Array System platform, followed by NGS 
sequencing, have been validated for the detection of FH-causing 
mutations. We show excellent performance for both approaches 
and discuss their potential for clinical screening programs and 
discovery of novel FH-causing genes.
MaTeRials and MeThods
Patients
We studied two groups of patients, a validation group includ-
ing patients with known molecular diagnosis and a prospec-
tive cohort of previously unscreened FH patients. In the vali-
dation group, DNA from 104 patients from the Hammersmith 
Hospital Lipid Clinic were analyzed. All 104 samples had previ-
ously undergone complete or partial screening of LDLR-coding 
regions and exon/intron boundaries, p.Asp374Tyr in PCSK9, 
and p.Arg3527Gln in APOB exon 26 using Sanger sequenc-
ing. In addition, MLPA was used to detect large deletions and 
duplications in a subset (>80%) of the patients in the valida-
tion cohort, as described in the study by Tosi et al.9 Forty-five 
samples were known to carry heterozygous FH-causing point 
mutations or small insertions/deletions (<20 bp) in LDLR, 
PCSK9, or APOB, and six had large heterozygous insertions/
deletions in LDLR. One sample was homozygous for LDLR 
p.Gln384Pro, and one sample was a compound heterozygote 
with one missense mutation and one large deletion in LDLR. 
The remaining 51 samples in the validation cohort had negative 
molecular diagnoses. Of the 104 samples, 29 were processed 
using the SureSelect Target Enrichment System alone, 42 using 
the Access Array System microfluidic platform alone, and the 
remaining 33 using both platforms. In the prospective cohort, 
84 consecutive patients referred for molecular testing by the 
Hammersmith Hospital Lipid Clinic over a period of 1 year 
were studied by the PCR-based Access Array System microflu-
idic platform. Fifteen of the 84 samples were also analyzed using 
the SureSelect Target Enrichment System. One individual was 
referred with suspected homozygous FH. All the remaining 83 
were suspected to be heterozygous. Six patients had a diagnosis 
of definite FH based on Simon Broome criteria. The median 
highest total cholesterol in this group was 9.7 mmol/l (mini-
mum: 7.9 mmol/l; maximum: 15.9 mmol/l). Sixty-five indi-
viduals had a diagnosis of possible FH, with a median highest 
total cholesterol level of 8.7 mmol/l (minimum: 5.2 mmol/l; 
maximum: 13 mmol/l), and 13 patients did not fulfill Simon 
Broome criteria. The median highest total cholesterol in this 
group was 8.3 mmol/l (minimum: 6.3 mmol/l; maximum: 9.6 
mmol/l). The mean age at measurement was 43 years (mini-
mum: 2 years; maximum: 68 years).
The study was approved under ethics committee references 
REC2002/6451 and REC11/LO/0883. All patients provided 
informed consent.
dna extraction
DNA was extracted from blood using a standard phenol–chlo-
roform protocol or the Maxwell 16 system (Promega, Madison, 
WI) or from saliva samples using the Oragene (Genotek, 
Ottawa, Ontario, Canada) protocol. Both protocols followed 
the manufacturer’s recommendations.
Rna extraction and reverse-transcription PCR
Blood for RNA extraction was collected in Tempus blood RNA 
tubes (Applied Biosystems, Foster City, CA) and extracted using 
the Paxgene blood RNA kit (Qiagen, Hilden, Germany) follow-
ing the manufacturer’s protocol. Reverse transcription was per-
formed using the iScript cDNA synthesis kit (BioRad, Hercules, 
CA). Primers (forward: TCGAGTTCCACTGCCTAAGTG 
and reverse: GTTGTTGTCCAAGCATTCGTT) were designed 
to amplify exons 4–7 of LDLR.
Custom sureselect Target enrichment system
Four genes with mutations known to cause FH (LDLR, APOB, 
PCSK9, and LDLRAP1), a myopathy-associated variant in 
SLCO1B1, and 13 genes (APOE, HMGCR, HNRNPD, INSIG1, 
KHSRP, NPC1L1, PTBP1, SREBF1, SREBF2, MESDC2, SCAP, 
INSIG2, and CYP7A1) functioning within cholesterol-process-
ing pathways were included in the SureSelect Target Enrichment 
System design (Agilent, Santa Clara, CA). The design contained 
120-mer baits spanning the entire nonrepetitive sequence of the 
selected genes, including exons and introns, 2 kb of upstream 
sequence (10 kb for the four known FH genes), and 1 kb of 
downstream sequence.
The genomic coordinates of the 18 targeted genes were 
determined using the March 2006 build (NCBI36/hg18) of the 
human genome in the Ensembl genome browser.12 The density 
of bait tiling was fivefold, and the baits were allowed to over-
lap into repeat regions by 30 bp. The total targeted DNA length 
was 399 kb. All libraries were generated from sheared DNA 
(Covaris, Woburn, MA) with an average insert size of 200 bp 
following the SureSelect Target Enrichment System XT proto-
col for Illumina multiplexed sequencing version 1.2 (Illumina, 
San Diego, CA). After dilution to 2 nmol/l, up to 30 libraries 
were pooled and sequenced on one lane on the HiSeq2000 plat-
form (Illumina) to generate 2 × 100 bp paired-end reads.
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PCR-based access array system
The design included 43 amplicons covering all exons of LDLR, 
with the majority of the coding sequence covered by more than 
one overlapping fragment. Amplicons were also designed to 
cover exons 2, 4, 7, and 9 of PCSK9, containing the most com-
mon gain-of-function pathogenic mutations; APOB (one ampli-
con covering the most common familial defective apolipoprotein 
B-100 mutation, p.Arg3527Gln); APOE (one amplicon covering 
the APOE E2 variant site, rs7412); and SLCO1B1 (one amplicon 
covering rs4149056, the myopathy-associated variant). The aver-
age amplicon length was 184 bp, with 57% GC content. Primer 
sequences are shown in Supplementary Table S1 online. Samples 
were processed using the Access Array System (Fluidigm, South 
San Francisco, CA) according to the manufacturer’s 4-Primer 
amplicon tagging protocol generating paired-end libraries for 
Illumina sequencing. Purified pooled products of 47 barcoded 
samples and one negative control were sequenced in one run 
using the MiSeq sequencer (Illumina). One amplicon, a GC-rich 
(75%) amplicon in APOE targeting rs7412, failed to amplify and 
was excluded from subsequent data analysis.
data analysis
Sequences were mapped to the GRCh37/hg19 human reference 
sequence using Burrows Wheeler Aligner v0.6.1.13 PCR dupli-
cate reads were removed from SureSelect Target Enrichment 
System data (Picard tools v1.35; http://picard.sourceforge.net). 
Sequence reads from both data sets were further processed, 
and variants were called using GATK v1.0.614 with hard filter-
ing options. Variant annotation was carried out with Ensembl’s 
Variant Effect Predictor tool12 and was based on the transcripts 
ENST00000558518 (LDLR), ENST00000233242 (APOB), 
and ENST00000302118 (PCSK9). The annotation included 
Sorting Intolerant From Tolerant, Condel, and PolyPhen. 
Conservation scores (Genomic Evolutionary Rate Profiling 
scores) were obtained from Ensembl12 version 68. To identify 
potentially pathogenic mutations, all nonsynonymous, splice 
site, frameshift, and truncating mutations were examined and 
compared with an FH locus–specific database6,15 as a guide 
to interpretation of variant pathogenicity. Synonymous and 
intronic variants located outside exon/intron boundaries as 
well as single-nucleotide polymorphisms with minor allele fre-
quency >1% in the International HapMap Project16 or the 1000 
Genomes Project17 were excluded from further analysis. All 
single-nucleotide variants and short insertions/deletions that 
were potentially disease causing were verified by conventional 
Sanger sequencing. Novel variants were followed up by segre-
gation analysis wherever possible.
Copy-number variant analysis
Copy-number variant (CNV) analysis from NGS data was 
performed for the samples sequenced using targeted capture. 
A read depth–based method,18 as implemented in R package 
ExomeDepth, was used to identify deletions and duplications 
spanning at least one exon. Each sequencing batch of samples 
was processed separately to increase the quality of a reference 
set for each sample and therefore to maximize the power to 
detect CNVs. Read depth was assessed for each exon in the tar-
get region, and the ratio of expected and observed read count 
was obtained, as well as a Bayes factor for the CNV calls, as 
implemented in the ExomeDepth method.
As an independent method of CNV analysis, MLPA was per-
formed using the kit LDLR-P062 (MRC-Holland, Amsterdam, 
The Netherlands) following the manufacturer’s protocol. The 
novel exon 16 deletion was confirmed by PCR. The previously 
described large deletions and duplications are detailed in the 
study by Tosi et al.9
statistical analysis
The sensitivity of an assay was defined as the percentage of 
pathogenic mutations correctly identified with respect to pre-
vious or new Sanger sequencing and MLPA. The specificity is 
defined as the percentage of mutation-negative samples cor-
rectly identified as negative with respect to previous or new 
Sanger sequencing and MLPA.
Myopathy-associated variant in SLCO1B1
Genotypes of the SLCO1B1 myopathy–associated variant 
rs4149056 were scored from the Access Array System microflu-
idic platform and SureSelect Targeted Enrichment System data 
in all patients, and any history of adverse effects was obtained 
by review of medical records. Side effects were defined bio-
chemically (transaminase or creatine kinase levels more than 
three times the upper limit of the normal range) or symptom-
atically for myalgia and other side effects that coincided tem-
porally with statin treatment. Tests for deviation from Hardy–
Weinberg equilibrium and association tests were performed 
using the DeFinetti software (http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl).
ResUlTs
Validation study
Custom SureSelect Target Enrichment System. To validate 
the assay, DNA was analyzed from 62 previously screened 
individuals who either had a confirmed molecular diagnosis 
of FH (n = 28) or were mutation-negative (n = 34). An 
average of 330 Gb (191–381 Gb) of sequence was obtained 
per sample, with an average coverage of ×827. Overall, 64% 
of total mapped reads aligned within the target region, and 
99.8 and 98.8% of nucleotides were covered at ×4 and ×25, 
respectively. The insufficiently covered regions are consistent 
among runs and were found mostly outside coding regions. 
Hybridization-based capture is known to target GC-rich 
regions poorly; however, all regions containing known 
FH-causing mutations were covered sufficiently (more 
than ×25) for confident variant calling. The initial analysis 
of the sequencing results was carried out by a researcher 
blinded to the gene and mutation details for each sample. 
All 20 heterozygous and 1 homozygous short pathogenic 
mutations, including point mutations and insertions/
deletions of <15 bp, were detected (Table 1). In addition, one 
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Table 1 Mutations identified in the validation study
id
detected by  
sureselect
detected by  
access array Gene cdna Protein
990 ND Yes APOB c.10580G>A p.Arg3527Gln
747 Yes Yes APOB c.10580G>A p.Arg3527Gln
1086 ND Yes APOB c.10580G>A p.Arg3527Gln
667 ND Yes PCSK9 c.385G>A p.Asp129Asn
735 ND Yes LDLR c.1618G>A p.Ala540Thr
604 Yes Yes LDLR c.1880C>A p.Ala627Asp
660 ND Yes LDLR c.1048C>T p.Arg350X
728 Yes Yes LDLR c.1048C>T p.Arg350X
631 Yes Yes LDLR c.2231G>A p.Arg744Gln
384 Yes Yes LDLR c.1217G>A p.ArgR406Gln
895 ND Yes LDLR c.1691A>G p.Asn564Ser
896 ND Yes LDLR c.1691A>G p.Asn564Ser
766 Yes Yes LDLR c.2061dupC p.Asn688Glnfs*29
430 Yes Yes LDLR c.661G>A p.Asp221Asn
570a Yes Yes LDLR c.681C>G p.Asp227Glu
862 ND Yes LDLR c.681C>G p.Asp227Glu
1095 ND Yes LDLR c.1444G>A p.Asp482Asn
438 Yes Yes LDLR c.1444G>C p.Asp482His
1031 ND Yes LDLR c.401G>A p.Cys134Tyr
714 Yes Yes LDLR c.939C>A p.Cys313X
1067 ND Yes LDLR c.1130G>A p.Cys377Tyr
1068 ND Yes LDLR c.1130G>A p.Cys377Tyr
819 Yes Yes LDLR c.2029T>C p.Cys677Arg
818 ND Yes LDLR c.2043C>A p.Cys681X
450 Yes Yes LDLR c.2043C>A p.Cys681X
814 Yes Yes LDLR c.2043C>A p.Cys681X
415 Yes Yes LDLR c.[1151A>C]; [1151A>C] p.Gln384Pro
813 ND Yes LDLR c.303delG p.Glu101Aspfs*105
996 ND Yes LDLR c.301G>A p.Glu101Lys
771 ND Yes LDLR c.301G>A p.Glu101Lys
820 ND Yes LDLR c.420G>C p.Glu140Asp
770 Yes Yes LDLR c.654_656delTGG p.Glu219del
586 Yes Yes LDLR c.682G>T p.Glu228X
1071 ND Yes LDLR c.1646G>A p.Gly549Asp
853 Yes Yes LDLR c.1436T>C p.Leu479Pro
857 Yes No LDLR c.2184_2194delGCTAAAGGTCA p.Lys730Hisfs*48
743 ND Yes LDLR c.1A>T p.Met?
663 Yes Yes LDLR c.1118_1121dupGTGG p.Tyr375Trpfs*7
764 Yes Yes LDLR c.1118_1121dupGTGG p.Tyr375Trpfs*7
1102 ND Yes LDLR c.1285G>A p.Val429Met
1104 ND Yes LDLR c.1285G>A p.Val429Met
666 Yes Yes LDLR c.1285G>A p.Val429Met
852 ND Yes LDLR c.1586+5G>C
1011 ND Yes LDLR c.1706-1G>T
1094 ND Yes LDLR c.1845+1G>A
721 ND Yes LDLR c.1845+11C>G
566 Yes Yes LDLR c.313+1G>A
556 Yes; Yes Yes; No LDLR c.[266G>A]; [2312-?_2547+?del] p.Cys89Tyr;  
Exons 16–17 deletion
683 Yes No LDLR c.-187-?_67+?del Promoter and exon 1 deletion
836a Yes No LDLR c.-187-?_67+?del Promoter and exon 1 deletion
547 Yes No LDLR c.-187-?_67+?del Promoter and exon 1 deletion
662a Yes no LDLR c.2312-?_2389+?del exon 16 deletion
436 Yes No LDLR c.695-?_817+?del Exon 5 deletion
564 Yes No LDLR c.68-?_2583+?del Exons 2–18 deletion
565 Yes No LDLR c.68-?_940+?del Exons 2–6 deletion
712 Yes No LDLR c.1187-?_2140+?dup Exons 9–14 duplication
Boldface indicates novel variants that were not previously identified.
cDNA, complementary DNA; ND, not done; ?, exact breakpoint boundaries not known.
aNew diagnosis in samples that had previously undergone partial screening only.
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compound heterozygote and six large insertions/deletions in 
the LDLR gene were detected, resulting in 100% sensitivity 
for this assay. No false positives were detected, and specificity 
for this assay was also 100%. A further three mutations were 
identified in LDLR in patients without a previous molecular 
diagnosis. One was a known single-nucleotide substitution, 
p.Asp227Glu, and two were large deletions (deletion of exon 
16 and deletion of promoter/exon 1). In addition, a novel 
variant was identified in the LDLR promoter (c. –227G>T; 
Genomic Evolutionary Rate Profiling score: 3.29; located in 
the highly conserved footprint 1 site), and two rare variants 
were identified in APOB in patients without a previous 
molecular diagnosis. The two variants, p.Pro877Leu 
(rs12714097) and p.Asp2213del (rs72653087), have not been 
described previously in FH patients and are not reported 
in either the 1000 Genomes Project17 or the International 
HapMap Project16 databases. No other rare missense variants 
were detected in the known FH genes in individuals without 
a molecular diagnosis.
PCR-based Access Array System. DNA samples from 53 
previously characterized patients including 40 with point 
mutations (39 heterozygotes and 1 homozygote), 6 with 
insertions/deletions (all heterozygotes), 6 with large deletions 
or duplications (all heterozygotes), and 1 compound 
heterozygote with 1 missense mutation and 1 large deletion 
in LDLR (Table  1) were amplified together with samples 
from 22 patients who had been previously screened as 
negative for mutations. The median coverage per sample was 
×572 (minimum: 461; maximum: 625). All amplicons except 
APOE (see Materials and Methods) amplified with a mean 
coverage of ×506. The coverage for individual amplicons is 
listed in Supplementary Table S2 online. Overall, 90% of 
bases were covered more than 25-fold. LDLR had a mean 
coverage of ×656 and >98% of bases were above ×25. All 
single-nucleotide changes in the coding sequence and 
intron/exon boundaries were correctly identified (Table 1), 
including one mutation in PCSK9 exon 2 and one in APOB, 
despite the lower sequencing coverage of these amplicons 
with 13 and 15 reads, respectively (the percentage of mutated 
alleles was 54 and 53%). One variant was not detected. This 
11 bp deletion (p.Lys730Hisfs*48) was not present in any 
aligned reads because the deletion overlapped with a forward 
primer, which prevented amplification of the mutated allele. 
The sensitivity for short variant detection was 98% (47 of 48), 
and specificity was 100%. Similar to the SureSelect Target 
Enrichment System results, one mutation, p.Asp227Glu, 
was identified in a sample that previously had no molecular 
diagnosis. No pathogenic mutations were found in the 
remaining samples that were negative on previous screening. 
Large deletions could not be detected with the PCR-based 
Access Array System because no reduction in coverage was 
observed within deleted regions. The overall sensitivity of 
this assay as compared with SureSelect Target Enrichment 
System was therefore 82% (47 of 57).
Prospective cohort
To test the feasibility of an NGS-based mutation screening in 
a clinical setting, a consecutive cohort of 84 unrelated patients 
referred for genetic screening over a single year was analyzed. 
Sixty-nine of these patients were screened using the Access 
Array System assay alone, and 15 were processed using both 
protocols. Sequencing and coverage metrics are provided in 
Supplementary Table S2 online. In total, 23 variants that 
have previously been reported as pathogenic in FH patients 
were identified in 22 individuals (Table 2), including 13 sin-
gle-nucleotide changes, 4 variants predicted to affect splicing, 
and 6 short insertions/deletions. In addition, two novel vari-
ants (p.Ala521Thr and p.Asn316Lysfs*54) were identified that 
had not been previously reported (Table 2). There was a good 
correlation between the results obtained from the Access Array 
System assay and SureSelect Target Enrichment System, with 
five of six mutations concordant between the data sets. The dis-
cordant variant, p.Lys730Hisfs*48, is the same one that was not 
detected using the Access Array System protocol in the vali-
dation cohort. Despite the presence of the same variant, these 
patients in the validation and prospective cohort were not 
known to be related. No additional mutations were identified 
using MLPA.
Of the two previously unreported variants (Table 2), the first 
was a missense change, p.Ala521Thr. This variant is conserved 
(Genomic Evolutionary Rate Profiling score: 2.66), is predicted 
to be damaging (PolyPhen score: 0.67, Sorting Intolerant From 
Tolerant score: 0.01, and Condel score: 0.643), and segregates 
with affected status in the family (Supplementary Figure S1a 
online). The second variant was a single-nucleotide deletion in 
exon 7 of LDLR, p.Asn316Lysfs*54. This frameshift mutation 
creates a premature stop codon and also segregates with hyper-
cholesterolemia in this family (Supplementary Figure  S1b 
online).
Two (c.817+1G>A and c.941-4G>A) of the four splice site 
variants identified (Table 2) were previously detected in FH 
patients,6 but their pathogenicity had not been experimentally 
validated before. An RNA sample was available for one of them 
(patient ID: 35) and reverse-transcriptase PCR in this patient 
showed that the c.817+1G>A variant disrupted correct splicing 
(data not shown). Alternative splice products were generated by 
partial intron retention that led to truncation of the protein, by 
exon skipping that caused the loss of exon 5 sequence, and by a 
predicted frameshift of the remaining protein. Of the remaining 
variants previously identified in FH patients, one missense vari-
ant, p.Val827Ile, was conservative, without a published proof of 
pathogenicity and therefore was considered to be of unknown 
significance. Two children of this index case were available for 
segregation analysis, and the results showed that an unaffected 
daughter (total cholesterol: 4.6 mmol/l; age: 27 years) of the 
proband had inherited the p.Val827Ile variant.
Mutation detection rates
The prospective cohort included six patients with definite FH as 
defined by the Simon Broome criteria, 65 with possible FH, and 
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13 hypercholesterolemic patients not fulfilling Simon Broome 
criteria for FH. The highest detection rate of clearly pathogenic 
mutations was in the group of patients with a definite FH diag-
nosis (4 of 6, 67%) followed by the group with a diagnosis of 
possible FH (17 of 65, 26%). One mutation (1 of 13, 8%) was 
identified among the 13 hypercholesterolemic patients who did 
not fulfill FH diagnostic criteria.
Variants in genes involved in cholesterol metabolism
In addition to the three known FH-causing genes and SLCO1B1, 
the SureSelect Target Enrichment System assay included 13 
genes that reside on cholesterol metabolism pathways. Rare 
variants identified in these genes, particularly in hypercho-
lesterolemic individuals who had been screened negative for 
mutations in LDLR, PCSK9, and APOB, are potentially respon-
sible for patients’ raised cholesterol levels. Rare variants (minor 
allele frequency < 0.01) identified in such individuals are listed 
in Supplementary Table S3 online. In patients with no previ-
ously known molecular diagnosis, seven rare nonsynonymous 
variants were found, of which six were not predicted to be 
functionally significant by Sorting Intolerant From Tolerant 
and PolyPhen. The single variant that was most likely to be of 
functional significance and therefore potentially pathogenic, 
was p.Val809Met in SREBF1. However, this was excluded from 
further analysis because it did not segregate with the phenotype 
in the family (data not shown).
SLCO1B1 myopathy-associated variant
Data on exposure to statins were available for 149 patients. 
Twenty-seven individuals were heterozygous for SLCO1B1 
rs4149056, and two were homozygous. One patient (a heterozy-
gote) had suffered severe biopsy-proven hepatitis while taking 
Table 2 Previously reported and novel variants identified in known disease-causing genes in the prospective cohort
dna  
id
detected 
by  
sureselect
detected  
by access  
array Gene cdna Protein
simon  
Broome  
criteria
age at  
measurement
highest total 
cholesterol 
(mmol/l)
1 Yes Yes LDLR c.938G>A p.Cys313Tyr Definite 48 15.9
2 nd Yes LDLR c.948delC p.asn316lysfs*54 definite 12 11.2
3 ND Yes LDLR c.190+4A>T Definite 44 9.4
5 ND Yes LDLR c.2479G>A p.Val827Ile Definite 58 7.9
6 ND Yes LDLR c.2054C>T/c.736delG p.Pro685Leu/ 
p.Gly246Glufs*19
Definite 2 9.7
9 Yes Yes LDLR c.1476_1477delCT p.Ser493Cysfs*42 Possible 20 9.2
12 Yes No LDLR c.2187_2197delAAAGGTCAGCT p.Lys730Hisfs*48 Possible 25 13.0
14 ND Yes LDLR c.204C>A p.Cys68* Possible 5 8.6
15 ND Yes LDLR c.1681C>T p.Gln561* Possible 3 5.2
18 ND Yes APOB c.10579C>T p.Arg3527Trp Possible 25 9.2
21 ND Yes LDLR c.1476_1477delCT p.Ser493Cysfs*42 Possible 29 8.1
22 Yes Yes LDLR c.283T>C p.Cys95Arg Possible 38 9.0
33 Yes Yes LDLR c.1561G>a p.ala521Thr Possible 33 10.0
35 Yes Yes LDLR c.817+1G>A Possible 13 10.5
40 ND Yes LDLR c.670_675delinsTTT p.Asp224_
Lys225delinsPhe
Possible 41 11.6
45 ND Yes LDLR c.1730G>A p.Trp577* Possible 56 10.3
50 ND Yes LDLR c.906C>G p.Cys302Trp Possible NA NA
52 ND Yes APOB c.10580G>A p.Arg3527Gln Possible 23 9.2
56 ND Yes LDLR c.266G>A p.Cys89Tyr Possible NA NA
58 ND Yes LDLR c.654_656delTGG p.Gly219del Possible 40 9.6
61 ND Yes LDLR c.941-4G>A Possible 43 NA
63 ND Yes LDLR c.2054C>T p.Pro685Leu Possible 11 9.0
68 ND Yes LDLR c.1130G>A p.Cys377Tyr Possible 12 7.0
72 ND Yes LDLR c.313+1G>A Not 
fulfilling 
criteria
47 9.6
Boldface indicates novel, not previously identified variants. These variants are expected to cause and were shown to segregate with the disease. Underlining indicates 
variants of unknown significance. These rare variants were previously reported in patients, but their pathogenicity has not been established.
cDNA, complementary DNA; NA, not available; ND, not done.
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statin drugs. A further 48 patients had suffered less-severe side 
effects, either patient-reported clinical effects or asymptomatic 
biochemical disturbances (Table 3). On association testing for 
rs4149056 in all individuals who had suffered side effects (n = 
49) versus those who had experienced no adverse effects on 
statins (n = 65), the odds ratio was 3.95 (confidence interval: 
1.58–9.89; P = 0.002).
disCUssion
We investigated the sensitivity and specificity of two target 
enrichment protocols, combined with NGS, for the detection of 
disease-causing mutations in patients with proven or suspected 
FH. Using the SureSelect Target Enrichment System and the 
HiSeq 2000 system, 98.8% of targeted regions were covered at 
more than ×25 as compared with the PCR-based Access Array 
System followed by MiSeq sequencing, for which on average 
10% of nucleotides failed to reach this coverage. Regions with 
low coverage were found outside the coding sequence of LDLR 
and mutation hotspots in APOB and PCSK9 and therefore did 
not affect the overall success of mutation detection. Both tech-
niques showed high sensitivity and specificity for the detection 
of single base substitutions and short insertions/deletions. In 
the validation part of the study, 100% of previously detected 
mutations were correctly identified using the SureSelect/HiSeq 
protocol. In comparison, the Access Array System/MiSeq 
approach led to correct identification of 98% of all variants 
detected previously by Sanger sequencing, although large inser-
tions/deletions could not be detected (see below). The single 
variant that was not detected by the PCR-based Access Array 
System protocol was an 11 bp deletion (p.Lys730Hisfs*48) that 
overlapped a primer site. However, the recent availability of lon-
ger sequencing reads, currently up to 250 bp when using MiSeq, 
will be anticipated in most cases to eliminate the need to have 
primer sites within coding regions or allow design modification 
to include longer overlaps between amplicons.
Three mutations in the LDLR coding sequence (one single-
nucleotide variant, p.Asp227Glu, and two large deletions) and 
one LDLR promoter variant (c.–227G>T) were identified in 
patients who were previously classified as negative for muta-
tions. Inspection of the previous laboratory database indicated 
that the p.Asp227Glu variant and the two large deletions had 
not been detected because of incomplete capillary sequenc-
ing in the case of the p.Asp227Glu and promoter variants and 
absence of MLPA data in the case of the two deletions.
A small proportion of FH cases are caused by large deletions 
or duplications of LDLR.19 The current standard screening is 
based on MLPA, a technique that is highly reliable but that is a 
costly and time-consuming addition to sequencing. The detec-
tion of large variants from NGS data has been shown previously, 
but its use in FH diagnostics has not yet been investigated.20,21 
Here, the combination of SureSelect Target Enrichment System/
HiSeq and data analysis using ExomeDepth software18 led to 
correct identification of all eight large deletions and one large 
duplication. This shows the potential of using hybrid capture 
for the detection of both short and large sequence variants in 
FH. The read depth from the PCR-based Access Array System 
assay was not used for this analysis method because read depth 
in this study did not correlate with exon deletions, although it 
has recently been shown that amplicon multiplex PCR can be 
optimized for CNV detection.22
When testing a new molecular workflow for routine diag-
nostics, in addition to sensitivity and specificity, it is important 
to consider the cost and time efficiency of the protocol. The 
SureSelect Target Enrichment System protocol allows for com-
prehensive coverage of targeted regions (current custom design 
up to 24 Mb), whereas the Access Array System protocol is lim-
ited to 480 amplicons with a maximum length of 400 bp when 
sequenced using the latest MiSeq system. Sequence capture 
also allows the detection of all types of variants, including large 
deletions and duplications, which was not possible in this study 
using the PCR-based Access Array System. On the other hand, 
the Access Array System is considerably cheaper to run,20,23 
with reagent costs approximately 10-fold lower than those for 
the SureSelect Target Enrichment System protocol,23 and, in 
addition, the library preparation turnaround time is shorter. 
In our hands, 96 samples can be processed within a day using 
the Access Array System protocol as compared with at least 
3 days needed for the SureSelect Target Enrichment System in-
solution capture. Initial DNA requirements of the Access Array 
System/MiSeq protocol are also low (50 ng vs. 1 ug), and most 
of the process is automated, reducing the risks of contamina-
tion and human error to a minimum. Recently, Hollants et al.24 
Table 3 The frequency of side effects of statin drugs in FH patients stratified by rs4149056
Total heterozygous homozygous Wild-type
Creatine kinase >3 times the upper limit of normal range 6 2 0 4
Creatine kinase ≤3 times the upper limit of normal range 5 1 1 3
Myalgia 12 3 1 8
Transaminase levels >3 times the upper limit of normal range 3 1 0 2
Transaminase levels ≤3 times the upper limit of normal range 9 2 0 7
Transaminase levels unknown 3 1 0 2
Other patient-reported side effects 11 4 0 7
Total 49 14 2 33
FH, familial hypercholesterolemia.
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published a protocol for FH mutation detection that was also 
based on the Access Array System, but the amplicons were 
sequenced using the pyrosequencing-based GS-FLX (Roche, 
Branford, CT) platform. They successfully identified all short 
variants but, as with our study, could not detect large rearrange-
ments. Our Access Array System protocol is here combined 
with the MiSeq sequencing platform (a benchtop personal NGS 
system specifically developed to suit the needs of the routine 
laboratory setting) and offers similar quality to GS-FLX but at 
a lower sequencing cost.25 The use of the MiSeq system is also 
reported to limit errors of variant calls within homopolymer 
regions that are known to occur in pyrosequencing.26
novel variants identified in the validation study
The LDLR promoter variant c.–227G>T has not previously been 
reported in FH patients, or in other populations, but was inves-
tigated previously as part of a study delineating the conserved 
footprint 1 site. A luciferase assay showed that the c. –227G>T 
variant had ~75% transcription levels as compared with the 
wild-type site.27 Although a 25% reduction is not a definitive 
decrease in promoter activity, it cannot be excluded that this 
change is sufficient to cause raised cholesterol levels in this 
patient. Family members were unavailable for segregation anal-
ysis, and we therefore classify this variant as being of uncertain 
significance pending further functional and segregation data. 
The remaining two novel variants in APOB, rs12714097 and 
rs72653087, were located outside LDLR-binding sites, regions 
currently not associated with hypercholesterolemia, and there-
fore their pathogenicity remains to be elucidated.
Genotype–phenotype correlation in the prospective cohort
In the United Kingdom, FH diagnosis is made based on the 
Simon Broome criteria that identify patients with definite or 
possible FH. Following the National Institute for Health and 
Clinical Excellence guidelines,6 genetic testing is recommended 
for all suspected index cases and should be followed by family 
cascade screening if a mutation is found. Our study focused on 
a group of consecutive patients referred for genetic screening by 
a local lipid clinic over the course of 1 year.
To assess clinical significance, all rare variants (minor allele 
frequency < 0.01) that were identified in LDLR, APOB, or 
PCSK9 were compared against locus-specific FH databases.6,15 
All nonsense variants and insertion/deletion variants that 
have been found previously among FH patients were also con-
sidered pathogenic. Missense variants were considered to be 
pathogenic if they were predicted by Sorting Intolerant From 
Tolerant and PolyPhen to be deleterious and probably damag-
ing, respectively, and were previously identified in FH patients. 
On the basis of these criteria, a missense change, p.Val827Ile, 
was included among the list of pathogenic variants, although 
the conservative valine to isoleucine substitution may not affect 
protein function. This residue is the third amino acid within the 
internalization signal for LDLR, NPVY, a position generally not 
necessary for correct internalization.28 In addition, our segrega-
tion data suggest that this variant may not be disease causing, 
and we therefore classified this variant as being of unknown sig-
nificance. Of the four splice site variants, three (c.313+1G>A, 
c.190+4A>T, and c.817+1G>A) were shown experimentally 
to disrupt splicing, two in published data29,30 and one within 
this study, and are therefore listed as pathogenic. The remain-
ing splice variant, c.941-4G>A, was described previously in FH 
patients, but its pathogenicity remains to be experimentally 
confirmed. An RNA sample from this individual was not avail-
able for confirmation within this study.
The mutation detection rates among patients with definite 
(66%) and possible (26%) FH are comparable to those of previ-
ously published studies.7 One mutation was identified among 
13 patients who did not fulfill Simon Broome criteria. This 
suggests that a number of patients with high cholesterol in the 
general population who do not fulfill formal clinical criteria for 
FH diagnosis may have FH-causing mutations. Such patients 
may therefore be diagnosed by the assays developed here, and, 
because these mutations are dominantly inherited, family cas-
cade screening would probably identify the same mutations in 
50% of their first-degree relatives.
The types of mutation identified here reflect the distribution of 
variants published in the LDLR locus–specific database,15 with 
exonic substitutions (56%) being the most common, followed 
by short insertions/deletions (28%). Most of the mutations 
identified here were unique, with only 20% common among 
UK FH patients that would be identified using the Elucigene 
FH20 commercial ARMS kit. In our prospective study, we did 
not identify any mutations in PCSK9 or large rearrangements 
of LDLR. These variants are generally rare among patients with 
FH,7 and we therefore consider it unlikely that our results are 
biased in any way.
Recently, the importance of screening additional regions of 
APOB has been highlighted by Motazacker et al.,31 who identi-
fied two patients with novel mutations located outside the com-
monly sequenced region of APOB exon 26. Screening of entire 
coding regions instead of focusing on mutation hot spots is 
therefore likely to enhance the discovery of FH-causing muta-
tions. The format of next-generation assays is flexible and can 
be readily extended to include full coding regions of APOB and 
PCSK9, as well as coding regions of other medically relevant 
genes, such as APOE and SLCO1B1, which currently need to be 
genotyped separately.
Our current Access Array System covers the same regions 
that would be screened using conventional Sanger sequenc-
ing, and therefore the number of variants identified would 
be no larger than that identified after Sanger sequencing. The 
SureSelect Target Enrichment System design also included 
genes in cholesterol metabolism pathways and regions of 
APOB and PCSK9 outside those known to be causative of 
FH. To establish the pathogenicity of such variants, further in 
silico and experimental analyses will be required. For detec-
tion of variants outside known FH-causing genes or gene 
regions, we focused on variants that are rare (minor allele fre-
quency < 0.01), are probably pathogenic (i.e., located in cod-
ing regions, promoters, and exon/intron boundaries), and 
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are present only in individuals without an existing molecular 
diagnosis of FH. Using these filters, we were left with a man-
ageable list of variants (<10) that we decided to follow up. 
When screening larger regions in more patients, the identifi-
cation of large numbers of variants of unknown significance 
will necessitate further extensive family segregation and 
functional assays. However, the increase of data available in 
public databases and improvements of bioinformatics tools 
will allow more efficient filtering of variants than is available 
at present.
statin-induced myopathy
Previous published data on larger cohorts show an odds ratio 
of 4.5 for association of rs4149056 with myopathy,32 and on that 
basis, guidelines have recommended avoiding higher doses of 
simvastatin in heterozygotes or homozygotes for rs4149056.33 
Association testing restricted to more severe side effects (trans-
aminases or creatine kinase greater than three times the upper 
limit of normal) was not informative in our cohort due to 
the small sample size. However, less-severe patient-reported 
adverse effects to statin treatment such as myalgia have an effect 
on patient adherence to treatment in this high-risk population. 
Therefore, the association identified here between SLCO1B1 
genotype and a wider range of milder adverse effects in this 
lipid clinic cohort gives an insight into the potential benefits of 
prospective genotyping before the initiation of statin treatment.
In conclusion, we have shown the potential utility of sequence 
target enrichment methods in combination with NGS in 
molecular diagnostics of FH. Owing to the comprehensive cov-
erage, SureSelect Target Enrichment System protocols (either 
whole-exome or region-specific) may provide the most ben-
efit for studies that aim to identify novel disease-causing genes 
and for diseases for which the number of genes needing to be 
screened is very large. In FH diagnostics for which <5 genes 
need to be analyzed, PCR-based enrichment techniques offer 
more streamlined protocols that provide high sensitivity for 
mutation detection and may offer an affordable option for clini-
cal screening of large numbers of patients with suspected FH. If 
adopted, greater numbers of FH patients and their relatives may 
potentially benefit from early diagnosis and treatment.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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